Weber Barbara
Known title: Chief Executive OfficerCIK: 0001800670
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
Transaction History
| TNGX | ▼ Sell | Open Market | 30,186 | $370K | 2/3/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 333 | $4K | 2/3/2026 | View on chart |
| TNGX | ▲ Buy | Grant | 37,522 | $0 | 2/2/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 9,013 | $28K | 2/5/2025 | View on chart |
| TNGX | ▼ Sell | Open Market | 9,778 | $29K | 2/4/2025 | View on chart |
| TNGX | ▲ Buy | Grant | 105,875 | $0 | 2/3/2025 | View on chart |
| RVMD | ▼ Sell | Open Market | 5,200 | $250K | 10/8/2024 | View on chart |
| RVMD | ▼ Sell | Other | 1,808 | $81K | 8/21/2024 | View on chart |
| RVMD | ▲ Buy | Grant | 4,800 | $0 | 6/20/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 4,457 | $56K | 2/7/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 4,681 | $59K | 2/6/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 87,168 | $0 | 2/1/2024 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 3,854 | $4K | 9/1/2023 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 11,146 | $53K | 9/1/2023 | View on chart |
| RVMD | ▼ Sell | Open Market | 15,000 | $526K | 9/1/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 5,200 | $0 | 6/8/2023 | View on chart |
| TNGX | ▲ Buy | Grant | 89,545 | $0 | 3/1/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 5,200 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.